Literature DB >> 21069412

Effect of anemia on cardiac disorders in pre-dialysis patients immediately before starting hemodialysis.

Michio Kuwahara1, Soichiro Iimori, Tamaki Kuyama, Wataru Akita, Yoshihiro Mori, Tomoki Asai, Yusuke Tsukamoto, Susumu Adachi, Tatemitsu Rai, Shinichi Uchida, Sei Sasaki.   

Abstract

INTRODUCTION: Anemia is a common complication of patients with chronic kidney disease (CKD), which not only lowers their quality of life but also potentially causes cardiovascular diseases such as congestive heart failure and coronary heart disease, and accelerates the progression of renal dysfunction.
METHODS: Pre-dialysis patients were assigned to groups A, B, C or D based on hemoglobin levels of ≤ 8.9 (n = 48), 9.0-9.9 (n = 63), 10-10.9 (n = 53), and ≥ 11.0 g/dL (n = 39), respectively. Cardiac function was estimated using echocardiography to clarify the relationship between anemia and cardiac disorders in patients with CKD immediately before starting hemodialysis.
RESULTS: Left ventricular ejection fraction (LVEF) was significantly higher in group D than in groups A and B. The fractions with an LVEF of less than 50% were 16.7, 4.8, 1.9, and 0% in groups A, B, C, and D, respectively. Posterior wall thickness was statistically thicker and the deceleration time of the early diastolic wave was longer in groups A and B, respectively, than in groups C and D. The left ventricular mass index in group D was significantly lower than in any other groups.
CONCLUSION: Anemia in pre-dialysis patients with CKD is a probable cause of impaired left ventricular systolic function and progressive left ventricular hypertrophy. Our results suggest that Hb levels should be maintained at >11 g/dL by EPO administration from the perspective of protecting cardiac function, although the upper limit of the target Hb level was undetermined.

Entities:  

Mesh:

Year:  2010        PMID: 21069412     DOI: 10.1007/s10157-010-0360-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  22 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

Review 2.  The clinical epidemiology of cardiac disease in chronic renal failure.

Authors:  P S Parfrey; R N Foley
Journal:  J Am Soc Nephrol       Date:  1999-07       Impact factor: 10.121

3.  Relationship between hematocrit and renal function in men and women.

Authors:  C Y Hsu; D W Bates; G J Kuperman; G C Curhan
Journal:  Kidney Int       Date:  2001-02       Impact factor: 10.612

4.  Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure.

Authors:  T Hayashi; A Suzuki; T Shoji; M Togawa; N Okada; Y Tsubakihara; E Imai; M Hori
Journal:  Am J Kidney Dis       Date:  2000-02       Impact factor: 8.860

5.  The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations.

Authors:  D S Silverberg; D Wexler; M Blum; G Keren; D Sheps; E Leibovitch; D Brosh; S Laniado; D Schwartz; T Yachnin; I Shapira; D Gavish; R Baruch; B Koifman; C Kaplan; S Steinbruch; A Iaina
Journal:  J Am Coll Cardiol       Date:  2000-06       Impact factor: 24.094

6.  Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.

Authors:  Helga Frank; Karsten Heusser; Bernd Höffken; Peter Huber; Roland E Schmieder; Hans P Schobel
Journal:  Kidney Int       Date:  2004-08       Impact factor: 10.612

7.  Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Mark J Sarnak; Hocine Tighiouart; Guruprasad Manjunath; Bonnie MacLeod; John Griffith; Deeb Salem; Andrew S Levey
Journal:  J Am Coll Cardiol       Date:  2002-07-03       Impact factor: 24.094

8.  Anemia is an independent predictor of mortality after percutaneous coronary intervention.

Authors:  Paul C Lee; Annapoorna S Kini; Chowdhury Ahsan; Edward Fisher; Samin K Sharma
Journal:  J Am Coll Cardiol       Date:  2004-08-04       Impact factor: 24.094

9.  Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients.

Authors:  D Roth; R D Smith; G Schulman; T I Steinman; F E Hatch; M R Rudnick; J A Sloand; B I Freedman; W W Williams; C A Shadur
Journal:  Am J Kidney Dis       Date:  1994-11       Impact factor: 8.860

10.  The prognostic importance of left ventricular geometry in uremic cardiomyopathy.

Authors:  R N Foley; P S Parfrey; J D Harnett; G M Kent; D C Murray; P E Barré
Journal:  J Am Soc Nephrol       Date:  1995-06       Impact factor: 10.121

View more
  4 in total

1.  Longitudinal changes in hematocrit in hypertensive chronic kidney disease: results from the African-American Study of Kidney Disease and Hypertension (AASK).

Authors:  Teresa K Chen; Michelle M Estrella; Brad C Astor; Tom Greene; Xuelei Wang; Morgan E Grams; Lawrence J Appel
Journal:  Nephrol Dial Transplant       Date:  2015-03-27       Impact factor: 5.992

2.  Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.

Authors:  Michio Kuwahara; Shintaro Mandai; Yuri Kasagi; Keita Kusaka; Tomomi Tanaka; Satomi Shikuma; Wataru Akita
Journal:  Clin Exp Nephrol       Date:  2014-09-03       Impact factor: 2.801

3.  Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients.

Authors:  Michio Kuwahara; Syoko Hasumi; Shintaro Mandai; Tomomi Tanaka; Satomi Shikuma; Wataru Akita; Yoshihiro Mori; Sei Sasaki
Journal:  Clin Exp Nephrol       Date:  2013-12-07       Impact factor: 2.801

Review 4.  Influence of chronic kidney disease on cardiac structure and function.

Authors:  Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh
Journal:  Curr Hypertens Rep       Date:  2015-09       Impact factor: 5.369

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.